Verzenio (abemaciclib)
Numéro de dossier de l’AMC:
23271
État des négociations:
Négociation envisagée
Indication(s):
For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer as follows: • in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy. • in combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone (GnRH) agonist. • as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens. At least one chemotherapy...
Promoteur/fabricant:
Eli Lilly Canada Inc.
Numéro de projet de l’AMC:
PC0409-000
Lettre d’entente de l’APP:
Sans objet
Conclusion du processus de négociation:
Sans objet